To overcome the immunosuppressive microenvironment, Li et al. [146] engineered T cells to secrete checkpoint inhibitors targeting PDCD1 (CAR.αPD1-T) and investigated their therapeutic efficacy in a human lung cancer xenograft mouse model. This evidence concerns the gene PDCD1 and lung carcinoma.